Pharmacological properties

Immunological properties. alfarekin — a dosage form of interferon alpha 2b human recombinant, synthesized by colibacillus cells on the basis of the gene coding the product identical to interferon alpha 2b the person with use of fagozavisimy genetically engineered biotechnology. alfarekin, as well as natural leukocytic interferon, has a wide range of biological activity.

Pharmacodynamics. The expressed antiviral and immunopromoting effect and also activation of antineoplastic protection has paramount value. Interferon regulates relationship between links of cell-mediated and antibody-mediated immunity. Under the influence of interferon the differentiation and activity of cells of natural killers and T lymphocytes raises, the active course of reactions of cell-mediated immunity is defined. Interferona regulate products of mediators of inflammation, influence migration of cages of inflammation in the pathological center, stimulate phagocytosis and other reactions of bacterial action, normalizing dynamics of inflammatory process. The antiallergic effect of medicine is defined by influence of interferon on an expression of molecules of the main complex of histocompatability and a tsitokinovy range. Interferona directly influence the main stages of replication of intracellular activators, stop their reproduction, provide effective lysis of infectious agents. Interferona are characterized by high antiviral and anti-chlamydial activity.

Use of the medicine Alfarekin as a part of complex treatment of chronic infectious and inflammatory diseases allows to increase efficiency of the antibacterial and other medicaments used for treatment and also to reduce their systemic toxic action, to reduce treatment duration.

Indication

Alfarekin in suppositories is applied at children and adults in the form of monotherapy and as a part of complex treatment at various viral and virus and bacterial infections. medicine is shown for application at infectious and inflammatory diseases of a respiratory and urogenital path, a dysplasia of a neck of the uterus, meningitis, sepsis, children's viral infectious diseases (measles, a rubella, chicken pox, epidemic parotitis), for the purpose of rehabilitation of the children who often have respiratory infections.

Use

Drug for rectal application.

is established by

In the diseases having a long course, a course of treatment Alfarekin individually taking into account a clinical picture and course of disease.

In complex therapy of infectious and inflammatory diseases (SARS, flu, pneumonia, sepsis, meningitis, etc.) at children at the age of 3 months-1 year are applied Alfarekin on 250 thousand ME by 2 times a day within 5 days. In case of need courses of treatment can be repeated with an interval of 5 days.

In complex therapy of virus and bacterial infections at children at the age of 1–7 years 2 times a day within 10 days use the medicament Alfarekin on 250 thousand ME, 7 years and adults are aged more senior — on 500 thousand ME 2 times a day within 10 days. Further it is possible to appoint the supporting medicament treatment of interferon within 1–12 months according to the individual scheme.

Therapy of flu and SARS at children at the age of 1 year-7 of years 2 times a day within 5 days, aged from 7 years carry out by the medicine Alfarekin in a dose 250 thousand ME — on 500 thousand ME 2 times a day within 5 days. At a heavy course of a SARS and flu the single dose is doubled.

by

For treatment of epidemic parotitis, measles, a rubella, chicken pox to children at the age of 1 year-7 of years Alfarekin 2 times a day within 5 days appoint in a dose 250 thousand ME. To children 7 years medicine are aged more senior appoint 500 thousand ME 2 times a day within 5 days.

For treatment of a rotavirus infection the medicine Alfarekin is appointed to children at the age of 3 months-1 year in a dose of 250 thousand ME of 1 times a day, to children at the age of 1–3 years — on 500 thousand. ME of 1 times a day, 3–7 years — on 500 thousand ME 2 times a day. Duration of treatment is 5 days.

In complex treatment of chronic infectious and inflammatory diseases of an urogenital path at adults is applied Alfarekin on 1 million ME of 1 times a day within 10 days. Treatment is carried out to both sexual partners.

In complex treatment of a dysplasia of a neck of the uterus is applied Alfarekin on 3 million ME daily within 10 days. The combination antibacterial (taking into account sensitivity of the activator) and antiviral treatment by Alfarekin has to precede tool destruction of the injured dysplastic epithelium. In case of need carrying out diatermo- or a cryolysis of a neck of the uterus carry out the Alfarekin medicament treatment also during the rehabilitation period in the same dose.

Rehabilitation therapy to children at the age of 1 year-7 of the years which often have recurrent virus and bacterial infections of a respiratory path, ENT organs, the recurrent diseases caused by a virus of a herpes simplex of the 1st type is carried out by suppositories Alfarekin according to the following scheme:

2 times a day within 10 days → on 250 thousand ME 2 times a day 3 times a week during 2 weeks → on 250 thousand ME 2 times a day 2 times a week during 2 weeks → on 250 thousand ME of 1 times for the night 2 times a week during 2 weeks → on 250 thousand ME of 1 times for the night once a week during 2 weeks

to Children at the age of 7–14 years carry out therapy by

• on 250 thousand ME according to the same scheme, using a medical dose of 500 thousand ME.

  Duration of a course is 2 months

  Contraindication

  Hypersensitivity to interferon alpha 2b or to other components of medicine.

  Side effects

  At basic courses of treatment suppositories alfarekin in the recommended doses the side effects are not observed by

  .

  Rectal method of administration of medicine is not followed by the significant collateral manifestations which are usually observed at parenteral administration of medicines of interferon. In some cases in the first days of treatment there can be grippopodobny symptoms which decrease further and disappear. It is possible to apply paracetamol in the doses corresponding to age of the patient to their prevention.

  Prolonged use of interferon in high doses can cause changes of composition of blood (leukopenia, thrombocytopenia, anemia), increase in the AlAT, AsAT, SF level, a sleep disorder, fluctuation of the ABP. These effects of a dozozavisima are also eliminated by a dose decline.

  Special instructions

  Alfarekin should be applied under observation of the doctor. patients should be informed on advantages of this therapy and possible side reactions. if side reaction does not weaken or amplifies, the dose is reduced to 50% or treatment is stopped.

  Alcohol intake is excluded by

  .

  should appoint by

  With care medicine in the presence in the anamnesis of such diseases as diabetes with ketoacidosis episodes, and chronic obstructive diseases of lungs, violations of blood clotting, the expressed myelosuppression.

  Use during pregnancy or feeding by a breast. Data on use of medicine during pregnancy and feeding by a breast are absent.

  Ability to influence speed of response when driving or other mechanisms. Treatment can be followed by drowsiness, weakness, fatigue and to lead to reduction in the rate of psychomotor reactions. In such cases it is necessary to refrain from control of vehicles and work with other mechanisms.

  Alfarekin is compatible

  Interaction

  to antibiotics, hormones which are applied at treatment of viral, virus and bacterial, autoimmune diseases.
  As interferon the alpha changes

  cellular metabolism, there is potentiality of modification of effect of other medicines. Interferon the alpha can change oxidizing metabolic processes that should be considered at co-administration of medicines which are metabolized in this way (Cimetidinum, Phenytoinum, warfarin, theophylline, Aminophyllinum, diazepam, propranolol).

  With care should use medicament along with opioid medicines, analgetics, hypnotic medicaments and sedative medicines (potentially cause myelosuppressive effect).

  Overdose

  Cases of sharp overdose of medicine it was not noted p.

  Storage conditions

  to Store

  in original packing at a temperature of 2-8 °C.